Abdulhaq, H., Townsend, W., Ku, M., Gregory, G. P., Abramson, J., Huang, H., Zhang, H., Yoon, D. H., Kim, W., Ghesquieres, H., Hertzberg, M., Zhang, Q., Kesavan, M., Mulvihill, E., Kallemeijn, M. J., Ta, R., Choeurng, V., Lundberg, L., Fox, C. (2025). Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups. Blood. https://doi.org/10.1182/blood-2025-3743